Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 20/20 | 0.62 |
| ▸ | CYP11B2 | P19099 | 20/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21535322 | 0.85 | CYP11B1 (0.59) | CYP11B1CYP11B2 | |
| SCHEMBL31260048 | 0.85 | CYP11B2 (0.59) | CYP11B1CYP11B2 | |
| SCHEMBL14789984 | 0.85 | CYP11B2 (0.59) | CYP11B1CYP11B2 | |
| SCHEMBL14780224 | 0.84 | CYP11B1 (0.67) | CYP11B1CYP11B2 | |
| SCHEMBL12593133 | 0.83 | CYP11B1 (0.69) | CYP11B1CYP11B2 | |
| SCHEMBL14789985 | 0.79 | CYP11B2 (0.58) | CYP11B1CYP11B2 | |
| SCHEMBL22005312 | 0.79 | CYP11B1 (0.58) | CYP11B1CYP11B2 | |
| SCHEMBL31259999 | 0.79 | CYP11B2 (0.58) | CYP11B1CYP11B2 | |
| SCHEMBL14786120 | 0.78 | CYP11B1 (0.65) | CYP11B1CYP11B2 | |
| SCHEMBL1762368 | 0.77 | CYP11B1 (1.00) | CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2755963-B1 | NEW DIHYDROQUINOLINE-2-ONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2019-10-30 | — | — | EP | claimed |
| EP-2755963-A1 | NEW DIHYDROQUINOLINE-2-ONE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2014-07-23 | — | — | EP | claimed |
| WO-2013037779-A1 | NEW DIHYDROQUINOLINE-2-ONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2013-03-21 | — | — | WO | claimed |
| US-20160193212-A1 | CYCLOPROPYL MODULATORS OF P2Y12 RECEPTOR | AUSPEX PHARMACEUTICALS INC (US) | 2016-07-07 | — | — | US | disclosed |
| EP-2755963-A1 | NEW DIHYDROQUINOLINE-2-ONE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2014-07-23 | — | — | EP | disclosed |
| WO-2013037779-A1 | NEW DIHYDROQUINOLINE-2-ONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2013-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160193212-A1 | CYCLOPROPYL MODULATORS OF P2Y12 RECEPTOR | P2RY12, P2RY11, P2RY2 | CYP11B1 1089/4885CYP11B2 1068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.